Peter Nygren

Uppsala University Hospital, Uppsala University

Papers

Total Citations

248

H-Index

About

Peter Nygren is a pioneering oncologist whose research has fundamentally advanced the field of cancer pharmacology and personalized medicine. His key contributions center on developing innovative methodologies for assessing cancer cell sensitivity to chemotherapeutic agents, most notably through the creation of the fluorometric microculture cytotoxicity assay (FMCA). This groundbreaking technique, detailed in his most cited work (236 citations), revolutionized how researchers evaluate drug efficacy by enabling rapid, high-throughput screening of patient tumor cells against a panel of potential treatments. Nygren's work has been instrumental in bridging the gap between laboratory research and clinical application, providing oncologists with practical tools to tailor chemotherapy regimens to individual patients. His later research expanded into molecular diagnostics, exploring signaling biomarkers for colorectal cancer diagnosis through high-sensitivity isoelectric focusing. By integrating functional drug sensitivity testing with molecular profiling, Nygren has helped establish the foundation for precision oncology, where treatment decisions are guided by both the genetic characteristics of tumors and their real-time pharmacological responses. His enduring impact is reflected in the continued clinical use of his methodologies and their influence on subsequent generations of cancer researchers.